Disease free survival as surrogate end-point for overall survival in adjuvant taxane-based chemotherapy for breast cancer: Analysis of randomized clinical trials

被引：0
|
作者：
Ciccarese, M. [1 ]
Bria, E. [1 ]
Cuppone, F. [1 ]
Nistico, C. [1 ]
Carlini, P. [1 ]
Natoli, G. [1 ]
Nuzzo, C. [1 ]
Terzoli, E. [1 ]
Cognetti, F. [1 ]
Giannarelli, D. [1 ]
机构：
[1] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI15 / XI15
页数：1
相关论文
共 50 条
  • [1] Three-year disease-free survival (DFS) as surrogate end-point for predicting five-year overall survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC): Analysis of 10 randomized clinical trials (RCTs)
    Giannarelli, D.
    Bria, E.
    Cuppone, F.
    Ciccarese, M.
    Nistico, C.
    Carlini, P.
    Milella, M.
    Lorusso, V.
    Terzoli, E.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Is 3-yrs disease-free-survival (DFS) a reliable surrogate end-point for predicting 5-yrs overall-survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC)? Analysis of randomized clinical trials (RCTS)
    Ciccarese, Mariangela
    Bria, Emilio
    Cuppone, Federica
    Carlini, Paolo
    Milella, Michele
    Sperduti, Isabella
    Lo Russo, Vito
    Nistico, Cecilia
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2007, 18 : 51 - 51
  • [3] Does 5-year disease-free survival correlate with 5-year overall survival in adjuvant taxane-based chemotherapy for breast cancer? Analysis of randomized clinical trials
    Cuppone, Federica
    Bria, Emilio
    Ciccarese, Mariangela
    Nistico, Cecilia
    Carlini, Paolo
    Natoli, Guido
    Nuzzo, Carmen
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2006, 17 : 98 - 98
  • [4] Should disease free survival (DFS) be used as surrogate end-point for overall survival (OS) in randomized clinical trials (RCTS) exploring adjuvant aromatase inhibitors (AIS) for breast cancer (BC)? Update of a meta-analysis looking at the magnitude of the benefit
    Cuppone, Federica
    Bria, Emilio
    Ciccarese, Mariangela
    Nistico, Cecilia
    Carlini, Paolo
    Sperduti, Isabella
    Lorusso, Vito
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2007, 18 : 50 - 50
  • [5] Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials
    Petrelli, Fausto
    Tomasello, Gianluca
    Ghidini, Michele
    Lonati, Veronica
    Passalacqua, Rodolfo
    Barni, Sandro
    HPB, 2017, 19 (11) : 944 - 950
  • [6] Should disease free survival (DFS) be used as a surrogate end-point in adjuvant chemotherapy trials for non-small-cell lung cancer (NSCLC)? Analysis of 7 randomized clinical trials (RCTS) exploring platinum-based chemotherapy
    Bria, Emilio
    Cecere, Fabiana Letizia
    Cuppone, Federica
    Nistico, Cecilia
    Milella, Michele
    Facciolo, Francesco
    Sperduti, Isabella
    Ceribelli, Anna
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2007, 18 : 34 - 34
  • [7] Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials
    De Laurentiis, Michele
    Cancello, Giuseppe
    D'Agostino, Diego
    Giuliano, Mario
    Giordano, Antonio
    Montagna, Emilia
    Lauria, Rossella
    Forestieri, Valeria
    Esposito, Angela
    Silvestro, Lucrezia
    Pennacchio, Roberta
    Criscitiello, Carmen
    Montanino, Agnese
    Limite, Gennaro
    Bianco, Angelo Raffaele
    De Placido, Sabino
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 44 - 53
  • [8] Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis
    Oba, Koji
    Paoletti, Xavier
    Alberts, Steven
    Bang, Yung-Jue
    Benedetti, Jacqueline
    Bleiberg, Harry
    Catalano, Paul
    Lordick, Florian
    Michiels, Stefan
    Morita, Satoshi
    Ohashi, Yasuo
    Pignon, Jean-pierre
    Rougier, Philippe
    Sasako, Mitsuru
    Sakamoto, Junichi
    Sargent, Daniel
    Shitara, Kohei
    Cutsem, Eric Van
    Buyse, Marc
    Burzykowski, Tomasz
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21): : 1600 - 1607
  • [9] Disease-free survival (DFS) as surrogate end point for overall survival (OS) in adjuvant aromatase inhibitors (AIs) trials for breast cancer (BC): Meta-analysis of 10 randomized clinical trials (RCTs) exploring the magnitude of the benefit
    Ciccarese, M.
    Bria, E.
    Cuppone, F.
    Nistico, C.
    Carlini, P.
    Sperduti, I.
    Lorusso, V.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] End points for adjuvant therapy trials: Has the time come to accept disease-free survival as a surrogate end point for overall survival?
    Gill, Sharlene
    Sargent, Daniel
    ONCOLOGIST, 2006, 11 (06): : 624 - 629
12345